Why ISRG Stock dropped -3.73% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, ISRG scores 75 out of 100, a letter grade of B, with the verdict label "Roarable Buy — Good Risk/Reward." The five pillars are: Fundamental Cash Engine at 16/20 (ROIC 15%; FCF yield 1.66%), Whale 13F Flow at 15/20 (institutional accumulation and options positioning), Insider Conviction at 12/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 14/20 (beta 0.97; sector sensitivity), and Forensic Balance Sheet at 18/20 (Altman Z 26; Piotroski F 9/9; Debt/Equity 0.06). The strongest pillar is the forensic balance sheet, which indicates low financial-distress risk per the metrics supplied. The weakest pillar is insider conviction, which signals less insider-side confirmation than the other pillars. Valuation is the central tradeoff: per the market data, the stock trades at a trailing P/E of 54.5, a forward P/E of 45.8, and an EV/EBITDA of 46, while the FCF yield is 1.66%. A prospective investor would be weighing a high-quality, low-leverage business against a premium price where near-term cash yield is thin, so returns would depend heavily on sustained growth rather than current cash distributions. This is an educational reading of the rating, not personalized advice.

Per the SEC financials, revenue rose from $7124.1M (FY 2023) to $10064.7M (FY 2025), and net income from $1798.0M to $2856.0M over the same span. Per the market data, operating margin is 29.3%, net margin 28.4%, and gross margin 66%, with ROIC at 15%. The Altman Z-Score is 26 and the Piotroski F-Score is 9/9, both per the Roarable RQD rating's forensic pillar, and Debt/Equity is 0.06. The FY 2023 debt figure ($20020.6M) is reported as provided in the source and is inconsistent in scale with the FY 2024 and FY 2025 figures; this discrepancy is not resolved in the source data.

Per the recent news wire, coverage in the window includes: a Yahoo Finance piece on the company's standing relative to Johnson & Johnson (headline only); an Investor's Business Daily report describing the stock as "hammered" as elevated buy-side views outshine solid numbers; a Trefis item asking what could lift the stock; a Seeking Alpha piece titled that the multiple fell but the story did not; a Yahoo Finance item on the stock beating a market upswing; and a Trefis item questioning whether the market price is justified. Signal lights are mixed: most items are flagged YELLOW, with one GREEN item labeled CATALYST. Risk watch: the IBD headline and Seeking Alpha framing point to multiple compression and sentiment pressure, while the GREEN catalyst item is the only positively flagged piece. Per the Butterfly Supply-Chain Graph, the single linked theme is GLP-1 metabolic drugs and bariatric procedure mix: Intuitive Surgical disclosed in its FY2024 Form 10-K that US bariatric volumes on da Vinci systems slowed as patients trialed GLP-1 drugs, with the exposure estimate labeled ~3%–4% of bariatric procedure mix. The graph classifies this as a potential loser with a mixed constraint and cites general surgery and da Vinci 5 upgrades as absorbing the drag. The proprietary signals list is empty.

Per the Butterfly Supply-Chain Graph, the supply_chain field is NONE and the sector/industry is Health Care / Industrial Specialties. The one documented link runs from NVO (Novo Nordisk, the GLP-1 drug source) to ISRG, typed POTENTIAL_LOSER with a CONFIRMED_FILING evidence tier. The mechanism is 2nd-order demand: GLP-1 weight-loss treatment reduces the bariatric surgery pipeline feeding da Vinci procedures. The source states bariatrics is under 5% of total global da Vinci procedures, limiting the magnitude. The competing explanation is that patients who plateau or lose coverage on GLP-1 therapy may re-enter the robotic bariatric funnel 12–24 months later. Watch item: the next catalyst named is Intuitive's quarterly worldwide procedure growth and bariatric sub-trend commentary. Upstream and downstream supplier dependencies are not available in source data.

• What is the FY 2023 debt figure of $20020.6M, given it is far out of scale with FY 2024 ($996.1M) and FY 2025 ($1132.7M)?
• Why is EPS reported as N/A across all three periods when trailing EPS is given as $8.24?
• What are the specific insider and 13F transactions underlying the 12/20 and 15/20 pillar scores?
• What is the FY 2023 cash balance, which is reported as N/A?
• How much of the 52-week price decline from $603.88 to a current $448.76 reflects the GLP-1 bariatric headwind versus broader multiple compression?